The generally excellent online magazine, Pharmaceutical Executive, is today running a post-mortem piece on the Not-Petya cyberattack / ransomware that struck Merck in June of 2017 (that bit is our backgrounder).
It is worthy reading -- in total, so do go read -- but here is a bit, while we await the reply of the plaintiffs, in the asylum TRO proceedings, in San Fran:
. . . .In the end, the most important thing for pharmaceutical companies, regardless of their size, to understand is that getting hit with this type of cyber attack is no longer a question of "if," but "when?" You can invest in all of the cybersecurity measures that you want -- it still won't prevent you from one day becoming the target of hackers with malicious intentions.
But if you know what someone is after, the good news is that you're now in a much better chance to mount the specific defense needed to protect it. That insight will act as your first line of defense against these types of cyber criminals in the future. . . .
Onward -- but I must note -- in Kenilworth's specific June 2017 case, it seems Merck was just collateral damage. The ultimate goal was not to steal pharma data, or disrupt the life science operations, specifically. It was to make a nefarious political statement in the Ukraine -- a likely Putin driven power move.
So there is some irony in that notion (not mentioned by the magazine, because it won't sell as much IT security consulting gig-work, in pharma proper). And now we look forward to seeing the next shoe fall, in reining in Trump's rampant lawlessness on vulnerable asylum seekers, tonight. . . and my grown kids start arriving early next week. Woot!
नमस्ते
No comments:
Post a Comment